VNCOP-B

From OncoWiki

Regimen

Cyclophosphamide 300 mg/m2 IV Weeks 1, 3, 5, 7
Mitoxantrone 10 mg/m2 IV Weeks 1, 3, 5, 7
Vincristine 2 mg IV Weeks 2, 4, 6, 8
Etoposide 150 mg/m2 IV Weeks 2, 6
Bleomycin 10 mg/m2 IV Weeks 4, 8
Prednisolone 40 mg PO daily, tapered over last 2 weeks 
G-CSF administration was 5 µg/kg/d subcutaneously throughout treatment, 
starting on day 3 of every week for 5 consecutive days
All patients receive cotrimoxazole prophylaxis	
This is an 8-week regime

References

Zinzani PL et al. Elderly aggressive-histology non-Hodgkin’s lymphoma: First-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94:33

Comments:
Complete remission (CR) was achieved by 202 (58%) patients and partial remission (PR) by 87 (25%), whereas the remaining 61 (17%) patients were nonresponders. The overall response rate (CR + PR) was 83%. Clinical and hematologic toxicities were modest, because 71% of the patients received granulocyte colony-stimulating factor (G-CSF). The CR rates for the three age groups (60 to 69, 70 to 79, and >= 80 years) were similar: 61%, 59%, and 56%, respectively. At 5 years, the relapse-free survival rate was 65%, the overall survival rate was 49%, and the failure-free survival rate was 33%.